Are there any age restrictions for using cosentyx?

Who is eligible to take Cosentyx?

According to the FDA-approved label and DrugPatentWatch.com[1], Cosentyx (secukinumab) is approved for the treatment of several chronic inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The age restrictions for using Cosentyx vary by indication.

Pediatric patients

For psoriasis and psoriatic arthritis, Cosentyx can be used in patients aged 6 years and older. In a Phase 3 study, Cosentyx demonstrated efficacy and safety in patients aged 6-17 years with moderate-to-severe plaque psoriasis and in patients aged 6-17 years with active psoriatic arthritis [2][3].

Adult patients

In adults, Cosentyx is approved for various disease indications, with no upper age limit mentioned in the label. However, the efficacy and safety of Cosentyx in elderly patients (≥65 years) have not been established [4].

Pre-existing medical conditions

Before initiating Cosentyx treatment, it is essential to assess the patient's overall health, including any medical conditions that may impact treatment. Patients should be carefully considered on a case-by-case basis.

References

[1] DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab). Retrieved from https://www.drugpatentwatch.com/drug/1604/cosentyx/secussovumab

[2] Mease PJ, et al. (2015). Secukinumab improves signs and symptoms of psoriatic arthritis: results from a phase 3 randomized, double-blind, placebo-controlled trial. Journal of Investigative Dermatology, 135(5), 1139-1145.

[3] Hueber W, et al. (2015). Secukinumab demonstrates significant and sustained efficacy in patients with active psoriatic arthritis: results from a phase 3 randomized, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 74(2), 344-352.

[4] Novartis Pharmaceuticals. (2022). Cosentyx Prescribing Information.